Am J Cancer 2002; 1 (5): 351-371 ADIS DRUG EVALUATION 1175-6357/02/0005-0351/$25.00/0 © Adis International Limited. All rights reserved. An Updated Review of its Use in Postmenopausal Women with Advanced Breast Cancer Gillian M. Keating and Blair Jarvis Adis International Inc., Langhorne, Pennsylvania, USA Various sections of the manuscript reviewed by: S. Chan, Department of Clinical Oncology, City Hospital, Nottingham, United Kingdom; M. de Lena, Operative Unit of Medical Oncology, Oncology Institute, Bari, Italy; J.M. Dixon, Breast Research Unit, Western General Hospital, Edinburgh, United Kingdom; W.J. Gradishar, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, USA; H.T. Mouridsen, Department of Oncology, The Finsen Center, Copenhagen, Denmark; S. Pyrhönen, Department of Oncology and Radiotherapy, Turku University Central Hospital, Turku, Finland. Data Selection Sources: Medical literature published in any language since October 1998 on Letrozole, identified using Medline and EMBASE, supplemented by AdisBase (a proprietary database of Adis International). Additional references were identified from the reference lists of published articles. Bibliographical information, including contributory unpublished data, was also requested from the company developing the drug. Search strategy: Medline search terms were ‘Letrozole’ or ‘CGS 20267’. EMBASE search terms were ‘Letrozole’ or ‘CGS 20267’. AdisBase search terms were ‘Letrozole’ or ‘CGS
American Journal of Cancer – Springer Journals
Published: Aug 10, 2012
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.